Nursing facility
Dignity Health
Dignity Health was paid $33.59M by Medicaid between Jan 2018 and Nov 2024, across 210 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 25% of everything it billed.
33Billing provider infoDIGNITY HEALTH
SANTA CRUZ, CA 95065
SANTA CRUZ, CA 95065
33aNPI1427181007assigned 03/13/2007
33bProvider typeSkilled Nursing Facility
28Total paid$33.59M
24GClaims741,459
24DCodes billed210
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Skilled Nursing Facility providers in California
Rank by total paid#6 of 547
Median peer was paid$73K
This provider vs. median459×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 97,755 | $4.35M | |
| 2019 | 120,641 | $4.82M | |
| 2020 | 94,020 | $3.99M | |
| 2021 | 103,301 | $4.65M | |
| 2022 | 111,930 | $5.33M | |
| 2023 | 117,646 | $5.71M | |
| 2024incomplete | 96,166 | $4.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 25% | 106,217 | 91,970 | $8.24M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 6,151 | 6,042 | $1.76M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.8% | 25,265 | 11,175 | $1.62M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 7,143 | 6,945 | $1.60M |
| 97799 | 4.6% | 33,835 | 8,355 | $1.55M | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 4.6% | 799 | 799 | $1.55M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.4% | 8,653 | 8,446 | $1.15M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 11,638 | 10,713 | $1.03M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 19,999 | 18,572 | $938K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.3% | 8,033 | 7,071 | $771K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.3% | 7,343 | 3,386 | $769K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 8,545 | 4,564 | $748K |
198 more codes
| 80053 | Comprehensive metabolic panel | 1.6% | 42,622 | $550K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 6,153 | $499K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 8,043 | $486K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 1,408 | $469K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 45,281 | $429K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 1.2% | 79,893 | $403K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 9,543 | $381K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 4,229 | $373K |
| 93971 | 1.0% | 1,957 | $344K | |
| 97165 | <1% | 3,745 | $323K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,616 | $317K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,932 | $274K |
| 99243 | <1% | 2,888 | $273K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 739 | $268K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,247 | $257K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,990 | $220K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,479 | $219K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,477 | $218K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 898 | $217K |
| 84484 | <1% | 13,144 | $197K | |
| 93976 | <1% | 405 | $145K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,609 | $138K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,358 | $137K |
| 76830 | Ultrasound, transvaginal | <1% | 1,319 | $135K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,789 | $134K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,550 | $131K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 592 | $131K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,695 | $127K |
| 83880 | <1% | 3,961 | $124K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,840 | $120K |
| 93975 | <1% | 321 | $118K | |
| 0450 | Emergency room services | <1% | 3,094 | $117K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,654 | $106K |
| 83690 | <1% | 12,295 | $104K | |
| 83605 | <1% | 6,936 | $103K | |
| 87040 | <1% | 4,322 | $98K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,119 | $96K |
| J3490 | Unclassified drugs | <1% | 2,352 | $93K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 253 | $90K |
| 84145 | <1% | 3,451 | $89K | |
| 59025 | Fetal non-stress test | <1% | 1,434 | $82K |
| 93970 | <1% | 273 | $78K | |
| 76770 | <1% | 711 | $77K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,767 | $75K |
| 87631 | <1% | 868 | $74K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,529 | $69K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,708 | $67K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 135 | $65K |
| 81001 | <1% | 15,829 | $63K | |
| 73610 | <1% | 1,426 | $62K | |
| 90715 | <1% | 642 | $62K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,981 | $61K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,886 | $59K |
| 97803 | <1% | 856 | $59K | |
| 73562 | <1% | 1,565 | $59K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,699 | $58K |
| 84703 | <1% | 5,733 | $53K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,819 | $50K |
| 73630 | <1% | 1,213 | $48K | |
| 87506 | <1% | 154 | $48K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,195 | $48K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 211 | $47K |
| 73030 | <1% | 1,039 | $44K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,021 | $40K |
| 12001 | <1% | 138 | $39K | |
| 83735 | <1% | 4,546 | $38K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,331 | $36K |
| 87186 | <1% | 3,014 | $35K | |
| 85027 | <1% | 4,383 | $35K | |
| 99283 | Emergency room visit (moderate) | <1% | 337 | $33K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,496 | $32K |
| 87430 | <1% | 2,008 | $32K | |
| Z7502 | <1% | 831 | $31K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 580 | $31K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,548 | $30K |
| 73130 | <1% | 722 | $30K | |
| 87077 | <1% | 3,089 | $29K | |
| 85610 | <1% | 5,850 | $28K | |
| 82962 | <1% | 4,140 | $26K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 183 | $25K |
| 94060 | <1% | 568 | $25K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 269 | $24K |
| 86850 | <1% | 2,233 | $24K | |
| 85730 | <1% | 3,393 | $24K | |
| 70486 | <1% | 74 | $23K | |
| 99284 | Emergency room visit (serious) | <1% | 94 | $23K |
| 10060 | <1% | 89 | $22K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,983 | $22K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,243 | $21K |
| 86141 | <1% | 1,558 | $21K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,301 | $21K |
| 73110 | <1% | 464 | $19K | |
| 72100 | <1% | 468 | $19K | |
| J1815 | Injection, insulin, per 5 units | <1% | 97 | $19K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,261 | $18K |
| 87081 | <1% | 2,066 | $18K | |
| 85379 | <1% | 1,417 | $18K | |
| 92522 | <1% | 91 | $17K | |
| 81003 | <1% | 6,154 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 790 | $17K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 55 | $17K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,046 | $16K |
| 84702 | <1% | 803 | $16K | |
| 94729 | <1% | 236 | $16K | |
| 76801 | <1% | 167 | $15K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,535 | $15K |
| 85007 | <1% | 3,280 | $14K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,518 | $14K |
| 84100 | <1% | 2,042 | $12K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,128 | $11K |
| 86901 | <1% | 2,795 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,084 | $10K |
| 94726 | <1% | 170 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 535 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 836 | $9K |
| 86900 | <1% | 2,346 | $9K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 33 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 346 | $9K |
| 29125 | <1% | 77 | $8K | |
| 82550 | <1% | 884 | $7K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 863 | $7K |
| 73080 | <1% | 166 | $7K | |
| 99199 | Unlisted special service, procedure or report | <1% | 139 | $7K |
| 85652 | <1% | 1,903 | $7K | |
| 87070 | <1% | 553 | $6K | |
| 86140 | <1% | 847 | $6K | |
| 97162 | <1% | 308 | $6K | |
| E1399 | Durable medical equipment, miscellaneous | <1% | 15 | $6K |
| 73140 | <1% | 185 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 440 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 970 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 594 | $5K |
| 87147 | <1% | 311 | $5K | |
| 97802 | <1% | 27 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 344 | $5K |
| 96367 | <1% | 80 | $5K | |
| 86803 | <1% | 247 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,427 | $4K |
| 72131 | <1% | 12 | $4K | |
| 76870 | <1% | 37 | $4K | |
| 10061 | <1% | 14 | $4K | |
| 96379 | <1% | 2,603 | $4K | |
| 80076 | <1% | 378 | $4K | |
| 86403 | <1% | 237 | $3K | |
| 86780 | <1% | 272 | $3K | |
| 87210 | <1% | 458 | $3K | |
| 80061 | Lipid panel | <1% | 254 | $3K |
| 71250 | <1% | 12 | $3K | |
| 99152 | <1% | 56 | $3K | |
| 87340 | <1% | 214 | $3K | |
| 92610 | <1% | 44 | $3K | |
| 73502 | <1% | 74 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 325 | $2K |
| 72040 | <1% | 67 | $2K | |
| 87420 | <1% | 134 | $2K | |
| 74018 | <1% | 83 | $2K | |
| 93797 | <1% | 174 | $2K | |
| 71101 | <1% | 39 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 35 | $2K |
| 73590 | <1% | 50 | $2K | |
| 86706 | <1% | 116 | $2K | |
| 84439 | <1% | 155 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 15 | $1K |
| 87205 | <1% | 220 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 55 | $1K |
| 82010 | <1% | 122 | $1K | |
| 97116 | <1% | 179 | $1K | |
| 86308 | <1% | 142 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 45 | $959.78 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 42 | $652.96 |
| 96415 | <1% | 17 | $636.16 | |
| 97161 | <1% | 16 | $533.26 | |
| 96523 | <1% | 13 | $421.29 | |
| 82570 | <1% | 63 | $405.44 | |
| 0270 | <1% | 233 | $393.43 | |
| 84156 | <1% | 101 | $382.92 | |
| 73090 | <1% | 12 | $366.18 | |
| 86709 | <1% | 28 | $363.55 | |
| 0250 | <1% | 44 | $340.49 | |
| 82728 | <1% | 20 | $329.63 | |
| 82803 | <1% | 13 | $286.96 | |
| 97166 | <1% | 12 | $269.71 | |
| 86708 | <1% | 16 | $215.15 | |
| 82140 | <1% | 12 | $210.68 | |
| 86790 | <1% | 12 | $193.38 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 19 | $190.35 |
| Z7610 | <1% | 129 | $97.96 | |
| 87088 | <1% | 13 | $93.45 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15 | $88.10 |
| 99070 | <1% | 37 | $81.65 | |
| 82565 | <1% | 12 | $79.37 | |
| 97018 | <1% | 64 | $38.27 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 43 | $0.37 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 70 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 71 | $0.00 |
| A9270 | Non-covered item or service | 0% | 25 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.